Eosinophilic esophagitis: Allergic contribution, testing, and management

被引:10
作者
Amindra A. Arora
Catherine R. Weiler
David A. Katzka
机构
[1] Department of Gastroenterology and Hepatology, Mayo Foundation, Rochester, MN 55905
[2] Department of Allergic Diseases, Mayo Foundation, Rochester, MN 55905
关键词
Allergy; Eosinophilic esophagitis; Esophagitis; Food antigens; Th2; pathway;
D O I
10.1007/s11894-012-0254-8
中图分类号
学科分类号
摘要
Both basic science and clinical data indicate a strong role for allergy as a cause of eosinophilic esophagitis. As a result, one of the desired goals of therapy is identification and elimination of food antigens that trigger the allergic inflammatory pathway. Traditional methods for identification of causative food antigens include induction of symptoms with exposure to the antigen, demonstration of serum IgE antibodies against antigens and induction of immediate (IgE) or delayed (Th2) reactions against dermal instillation of antigens. Although some data support the use of these tests in patients with eosinophilic esophagitis, they are limited in this disease. This limitation results from an inability to provoke recognizable symptoms and a lack of concordance between allergies identified in the skin and the blood with the antigens that trigger esophageal disease. As a result, allergy therapy in eosinophilic esophagitis consists of global elimination of food antigens with an elemental diet or exclusion of the most common antigens. As compliance is difficult with these strategies, the mainstay of allergy therapy in eosinophilic esophagitis has become the use of medications that blunt the allergic pathway such as steroids with a future aimed toward more specific inhibitors of this pathway in eosinophilic esophagitis specifically. © Springer Science+Business Media, LLC 2012.
引用
收藏
页码:206 / 215
页数:9
相关论文
共 64 条
[11]  
Lucendo A.J., Navarro M., Comas C., Pascual J.M., Burgos E., Santamaria L., Larrauri J., Immunophenotypic characterization and quantification of the epithelial inflammatory infiltrate in eosinophilic esophagitis through stereology: An analysis of the cellular mechanisms of the disease and the immunologic capacity of the esophagus, American Journal of Surgical Pathology, 31, 4, pp. 598-606, (2007)
[12]  
Mishra A., Hogan S.P., Brandt E.B., Rothenberg M.E., IL-5 promotes eosinophil trafficking to the esophagus, Journal of Immunology, 168, 5, pp. 2464-2469, (2002)
[13]  
Zhu X., Wang M., Mavi P., Rayapudi M., Pandey A.K., Kaul A., Putnam P.E., Rothenberg M.E., Mishra A., Interleukin-15 expression is increased in human eosinophilic esophagitis and mediates pathogenesis in mice, Gastroenterology, 139, pp. 182-193
[14]  
Zuo L., Fulkerson P.C., Finkelman F.D., Mingler M., Fischetti C.A., Blanchard C., Rothenberg M.E., IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R alpha 2-inhibited pathway, J Immunol, 185, pp. 660-669
[15]  
Blanchard C., Stucke E.M., Burwinkel K., Caldwell J.M., Collins M.H., Ahrens A., Buckmeier B.K., Jameson S.C., Greenberg A., Kaul A., Franciosi J.P., Kushner J.P., Martin L.J., Putnam P.E., Abonia J.P., Wells S.I., Rothenberg M.E., Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis, J Immunol, 184, pp. 4033-4041
[16]  
Blanchard C., Stucke E.M., Rodriguez-Jimenez B., Burwinkel K., Collins M.H., Ahrens A., Alexander E.S., Butz B.K., Jameson S.C., Kaul A., Franciosi J.P., Kushner J.P., Putnam P.E., Abonia J.P., Rothenberg M.E., A striking local esophageal cytokine expression profile in eosinophilic esophagitis, J Allergy Clin Immunol, 127, pp. 208-217
[17]  
Blanchard C., Wang N., Stringer K.F., Mishra A., Fulkerson P.C., Abonia J.P., Jameson S.C., Kirby C., Konikoff M.R., Collins M.H., Cohen M.B., Akers R., Hogan S.P., Assa'ad A.H., Putnam P.E., Aronow B.J., Rothenberg M.E., Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis, Journal of Clinical Investigation, 116, 2, pp. 536-547, (2006)
[18]  
Rothenberg M.E., Biology and treatment of eosinophilic esophagitis, Gastroenterology, 137, pp. 1238-1249, (2009)
[19]  
Protheroe C., Woodruff S.A., De Petris G., Mukkada V., Ochkur S.I., Janarthanan S., Lewis J.C., Pasha S., Lunsford T., Harris L., Sharma V.K., McGarry M.P., Lee N.A., Furuta G.T., Lee J.J., A novel histologic scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis, Clin Gastroenterol Hepatol, 7, pp. 749-755, (2009)
[20]  
Rubinstein E., Cho J.Y., Rosenthal P., Chao J., Miller M., Pham A., Aceves S.S., Varki A., Broide D.H., Siglec-F inhibition reduces esophageal eosinophilia and angiogenesis in a mouse model of eosinophilic esophagitis, J Pediatr Gastroenterol Nutr, 53, pp. 409-416